ERBB2 and breast carcinoma: Since the introduction of trastuzumab in the treatment of both early and advanced-stage disease, the prognosis has been significantly altered with improved survival such that this subtype of breast cancer arguably now has one of the better prognoses when treated with anti-HER-2 therapies [3–5].